Medidata NEXT New York to Unveil New Vision for Life Sciences Innovation 

  • Medidata to announce latest innovations to accelerate drug and device development to bring treatments to patients sooner
  • Signature event brings together life sciences leaders to experience the transformative power of artificial intelligence (AI), diversity programs, and decentralized clinical trials technology
  • Presenters will include Medidata customers such as BeiGene, Fortrea, Catalyst, Orion, Parexel, PROMETRIKA, QuidelOrtho, and Syneos Health, among others

NEW YORK--()--Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, will host NEXT New York 2023, the premier clinical research conference taking place in New York City from November 7- 8. The gathering of more than 700 life sciences leaders will provide a platform for attendees to experience groundbreaking innovations that push the boundaries of the life sciences value chain — from research to commercialization.

The event showcases how Medidata is transforming the clinical landscape and paving the way to deliver next-generation therapies. Sessions presented by Medidata customers from across the industry, including biopharmaceutical companies, contract research organizations, and research sites, will illustrate how industry-leading solutions, such as Medidata’s Platform, Rave, Patient Cloud, and AI offerings, are revolutionizing clinical trials by fueling faster, better insights. Medidata will also unveil a range of new offerings — from intelligent data automation advancements to AI-generated synthetic data — that will usher in a new era of patient-centric, smart data management and clinical development decision-making.

Interactive touch points and immersive experiences will be available throughout the conference, including a dedicated innovation lounge that will provide attendees with an opportunity to participate in a simulated decentralized clinical trial experience, engage with data management systems from a patient perspective, sign up for a clinical trial registry, and see new products in action.

“NEXT New York is a pivotal opportunity to reimagine the life sciences value chain and move the industry forward in ways far beyond clinical trials,” said Michael Pray, chief operating officer of Medidata. “Together with our customers and industry thought leaders, we are transforming the paradigm for life sciences in our pursuit to bring life-saving treatments to patients sooner.”

Register for the event and stay up to date on the latest agenda at MedidataNext2023.com.

About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.

Contacts

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
Medidata.AR@3ds.com

Contacts

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
Medidata.AR@3ds.com